Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share By
Mesenchymal Stromal Cells and Car-T Cells in Regenerative Medicine: The Homing Procedure and Their Effective Parameters Publisher Pubmed



Kolahi Azar H1, 2 ; Imanpour A2 ; Rezaee H2, 3 ; Ezzatifar F2, 4, 5 ; Zareibehjani Z2, 6 ; Rostami M7, 8 ; Azami M2, 9 ; Behestizadeh N2, 9 ; Rezaei N10, 11, 12
Authors

Source: European Journal of Haematology Published:2024


Abstract

Mesenchymal stromal cells (MSCs) and chimeric antigen receptor (CAR)-T cells are two core elements in cell therapy procedures. MSCs have significant immunomodulatory effects that alleviate inflammation in the tissue regeneration process, while administration of specific chemokines and adhesive molecules would primarily facilitate CAR-T cell trafficking into solid tumors. Multiple parameters affect cell homing, including the recipient's age, the number of cell passages, proper cell culture, and the delivery method. In addition, several chemokines are involved in the tumor microenvironment, affecting the homing procedure. This review discusses parameters that improve the efficiency of cell homing and significant cell therapy challenges. Emerging comprehensive mechanistic strategies such as non-systemic and systemic homing that revealed a significant role in cell therapy remodeling were also reviewed. Finally, the primary implications for the development of combination therapies that incorporate both MSCs and CAR-T cells for cancer treatment were discussed. © 2023 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Other Related Docs
7. Car-Modified T-Cell Therapy for Cancer: An Updated Review, Artificial Cells# Nanomedicine and Biotechnology (2016)
16. Crispr/Cas9 Revitalizes Adoptive T-Cell Therapy for Cancer Immunotherapy, Journal of Experimental and Clinical Cancer Research (2021)
18. Regenerative Medicine: Injectable Cell-Based Therapeutics and Approved Products, Advances in Experimental Medicine and Biology (2020)